ESTRO 2024 - Abstract Book

S1495

Clinical - Lower GI

ESTRO 2024

Conclusion:

IVIM-DWI is a promising non-invasive tool to identify responders from non-responders to neoadjuvant treatment for rectal cancer, potentially enabling more personalised treatment. Our findings indicate that baseline, inter fractional and entire treatment course evolution exhibit distinctions between the two groups in terms of D and p frac. In this regard, MR-Linac holds great promise, and the ongoing pre-post irradiation analyses could potentially offer a more precise exploration of early changes in the tumour. Further investigations with a larger sample size are required, and attention should be given to repeatability, along with a comprehensive analysis of the evolution of the tumour microenvironment.

Keywords: IVIM-DWI, MR-Linac, rectal cancer

842

Proffered Paper

Immunotherapy based total neoadjuvant therapy for locally advanced rectal cancer (TORCH NCT04518280)